{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T15:05:31Z","timestamp":1776179131805,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"AMED","doi-asserted-by":"crossref","award":["JP24fk0210117"],"award-info":[{"award-number":["JP24fk0210117"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm Regener"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>For the treatment of liver fibrosis, several novel cell therapies have been proposed. Autologous macrophage therapy has been reported as one of the promising treatments. So far, most studies have used colony-stimulating factor 1 (CSF-1) to induce the differentiation of macrophage progenitor cells. The receptor for CSF-1, CSF-1R possesses another ligand, interleukin 34. However, the therapeutic capacity for liver fibrosis by interleukin 34-induced macrophages has not been evaluated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We have employed acute (bile duct ligation) and chronic (administration of carbon tetrachloride or thioacetamide) liver fibrosis models. Using these models, we evaluated the therapeutic capacity of macrophages induced by interleukin 34-based conditions. In most experiments, interleukin 4 was also added to the differentiation process to induce alternative-activated macrophages. As a mechanism analysis, we have examined liver inflammation and damage, the status of stellate cells, and the immunosuppressive capacity of the macrophages. Human macrophages were differentiated from CD14<jats:sup>+<\/jats:sup> monocytes and analyzed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In both acute and chronic liver damage experiments, interleukin 34-induced macrophages significantly ameliorated liver fibrosis. The addition of interleukin 4 to the differentiation process resulted in an increase of obtained macrophages and a bias to alternative activated macrophages (so-called M2). The alternative activated macrophages (M2-type) showed a reproducible therapeutic effect of liver fibrosis with a suppression of parameters of liver inflammation and damage, stellate cells, and T cell activation. Similar macrophages could be differentiated from human CD14<jats:sup>+<\/jats:sup> monocytes in the presence of interleukin 34 plus interleukin 4, and a therapeutic effect was observed using a humanized mouse model.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Interleukin 34-induced macrophages, particularly when additionally stimulated with interleukin 4, significantly ameliorated the liver fibrosis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s41232-025-00364-7","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T07:46:04Z","timestamp":1737704764000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Amelioration of liver fibrosis with autologous macrophages induced by IL-34-based condition"],"prefix":"10.1186","volume":"45","author":[{"given":"Yuichi","family":"Igarashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruka","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Muto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryohei","family":"Sone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4122-1718","authenticated-orcid":false,"given":"Ken-ichiro","family":"Seino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"364_CR1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3389\/fphys.2016.00047","volume":"7","author":"P Wang","year":"2016","unstructured":"Wang P, Koyama Y, Liu X, Xu J, Ma HY, Liang S, Kim IH, Brenner DA, Kisseleva T. Promising therapy candidates for liver fibrosis. Front Physiol. 2016;7:47.","journal-title":"Front Physiol"},{"key":"364_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","volume":"70","author":"SK Asrani","year":"2019","unstructured":"Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70:151.","journal-title":"J Hepatol"},{"key":"364_CR3","doi-asserted-by":"publisher","first-page":"S157","DOI":"10.1016\/j.jhep.2015.02.040","volume":"62","author":"SJ Forbes","year":"2015","unstructured":"Forbes SJ, Gupta S, Dhawan A. Cell therapy for liver disease: from liver transplantation to cell factory. J Hepatol. 2015;62:S157.","journal-title":"J Hepatol"},{"key":"364_CR4","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1038\/s41591-019-0599-8","volume":"25","author":"F Moroni","year":"2019","unstructured":"Moroni F, Dwyer BJ, Graham C, Pass C, Bailey L, Ritchie L, Mitchell D, Glover A, Laurie A, Doig S, Hargreaves E, Fraser AR, Turner ML, Campbell JDM, McGowan NWA, Barry J, Moore JK, Hayes PC, Leeming DJ, Mielsen MJ, Musa K, Fallowfield JA, Forbes SJ. Safety profile of autologous macrophage therapy for liver cirrhosis. Nat Med. 2019;25:1560.","journal-title":"Nat Med"},{"key":"364_CR5","doi-asserted-by":"publisher","first-page":"a021857","DOI":"10.1101\/cshperspect.a021857","volume":"6","author":"ER Stanley","year":"2014","unstructured":"Stanley ER, Chitu V. CSF-1 receptor signaling in myeloid cells. Cold Spring Harb Perspect Biol. 2014;6:a021857.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"364_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cyto.2017.08.020","volume":"99","author":"M Baghdadi","year":"2017","unstructured":"Baghdadi M, Endo H, Tanaka Y, Wada H, Seino KI. Interleukin 34, from pathogenesis to clinical applications. Cytokine. 2017;99:139.","journal-title":"Cytokine"},{"key":"364_CR7","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/JLB.MR1117-457R","volume":"104","author":"M Baghdadi","year":"2018","unstructured":"Baghdadi M, Umeyama Y, Hama N, Kobayashi T, Han N, Wada H, Seino KI. Interleukin-34, a comprehensive review. J Leukoc Biol. 2018;104:931.","journal-title":"J Leukoc Biol"},{"key":"364_CR8","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/ni.2360","volume":"13","author":"Y Wang","year":"2012","unstructured":"Wang Y, Szretter KJ, Vermi W, Gilfillan S, Rossini C, Cella M, Barrow AD, Diamond MS, Colonna M. IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia. Nat Immunol. 2012;13:753.","journal-title":"Nat Immunol"},{"key":"364_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s41232-020-00129-4","volume":"40","author":"N Han","year":"2020","unstructured":"Han N, Anwar D, Hama N, Kobayashi T, Suzuki H, Takahashi H, Wada H, Otsuka R, Baghdadi M, Seino KI. Bromodomain-containing protein 4 regulates interleukin-34 expression in mouse ovarian cancer cells. Inflamm Regen. 2020;40:25.","journal-title":"Inflamm Regen"},{"key":"364_CR10","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/intimm\/dxz074","volume":"32","author":"H Endo","year":"2020","unstructured":"Endo H, Hama N, Baghdadi M, Ishikawa K, Otsuka R, Wada H, Asano H, Endo D, Konno Y, Kato T, Watari H, Tozawa A, Suzuki N, Yokose T, Takano A, Kato H, Miyagi Y, Daigo Y, Seino KI. Interleukin-34 expression in ovarian cancer: a possible correlation with disease progression. Int Immunol. 2020;32:175.","journal-title":"Int Immunol"},{"key":"364_CR11","doi-asserted-by":"publisher","first-page":"6030","DOI":"10.1158\/0008-5472.CAN-16-1170","volume":"76","author":"M Baghdadi","year":"2016","unstructured":"Baghdadi M, Wada H, Nakanishi S, Abe H, Han N, Putra WE, Endo D, Watari H, Sakuragi N, Hida Y, Kaga K, Miyagi Y, Yokose T, Takano A, Daigo Y, Seino KI. Chemotherapy-induced IL34 enhances immunosuppression by tumor-associated macrophages and mediates survival of chemoresistant lung cancer cells. Cancer Res. 2016;76:6030.","journal-title":"Cancer Res"},{"key":"364_CR12","doi-asserted-by":"publisher","first-page":"2238499","DOI":"10.1080\/2162402X.2023.2238499","volume":"12","author":"N Han","year":"2023","unstructured":"Han N, Wada H, Kobayashi T, Otsuka R, Seino KI. A mechanism of IL-34-induced resistance against cytotoxic anti-cancer therapies such as radiation by X-ray and chemotherapy by Oxaliplatin. Oncoimmunology. 2023;12:2238499.","journal-title":"Oncoimmunology"},{"key":"364_CR13","doi-asserted-by":"publisher","first-page":"101584","DOI":"10.1016\/j.isci.2020.101584","volume":"23","author":"N Hama","year":"2020","unstructured":"Hama N, Kobayashi T, Han N, Kitagawa F, Kajihara N, Otsuka R, Wada H, Lee HK, Rhee H, Hasegawa Y, Yagita H, Baghdadi M, Seino KI. Interleukin-34 limits the therapeutic effects of immune checkpoint blockade. iScience. 2020;23:101584.","journal-title":"iScience."},{"key":"364_CR14","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s00262-022-03293-3","volume":"72","author":"N Kajihara","year":"2023","unstructured":"Kajihara N, Kobayashi T, Otsuka R, Nio-Kobayashi J, Oshino T, Takahashi M, Imanishi S, Hashimoto A, Wada H, Seino K. Tumor-derived interleukin-34 creates an immunosuppressive and chemoresistant tumor microenvironment by modulating myeloid-derived suppressor cells in triple-negative breast cancer. Cancer Immunol Immunother. 2023;72:851.","journal-title":"Cancer Immunol Immunother"},{"key":"364_CR15","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/sji.12468","volume":"85","author":"YY Sun","year":"2017","unstructured":"Sun YY, Li XF, Meng XM, Huang C, Zhang L, Li J. Macrophage phenotype in liver injury and repair. Scand J Immunol. 2017;85:166.","journal-title":"Scand J Immunol"},{"key":"364_CR16","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1146\/annurev-physiol-022516-034339","volume":"79","author":"PJ Murray","year":"2017","unstructured":"Murray PJ. Macrophage Polarization. Annu Rev Physiol. 2017;79:541.","journal-title":"Annu Rev Physiol"},{"key":"364_CR17","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3390\/cells9040875","volume":"9","author":"N Roehlen","year":"2020","unstructured":"Roehlen N, Crouchet E, Baumert TF. Liver fibrosis: mechanistic concepts and therapeutic perspectives. Cells. 2020;9:875.","journal-title":"Cells"},{"key":"364_CR18","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nri.2017.90","volume":"18","author":"RL Gieseck 3rd","year":"2018","unstructured":"Gieseck RL 3rd, Wilson MS, Wynn TA. Type 2 immunity in tissue repair and fibrosis. Nat Rev Immunol. 2018;18:62.","journal-title":"Nat Rev Immunol"},{"key":"364_CR19","doi-asserted-by":"publisher","first-page":"803037","DOI":"10.3389\/fimmu.2021.803037","volume":"12","author":"C Wang","year":"2021","unstructured":"Wang C, Ma C, Gong L, Guo Y, Fu K, Zhang Y, Zhou H, Li Y. Macrophage polarization and its role in liver disease. Front Immunol. 2021;12:803037.","journal-title":"Front Immunol"},{"key":"364_CR20","first-page":"52438","volume":"96","author":"CG Tag","year":"2015","unstructured":"Tag CG, Sauer-Lehnen S, Weiskirchen S, Borkham-Kamphorst E, Tolba RH, Tacke F, Weiskirchen R. Bile duct ligation in mice: induction of inflammatory liver injury and fibrosis by obstructive cholestasis. J Vis Exp. 2015;96:52438.","journal-title":"J Vis Exp"},{"key":"364_CR21","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/BF01002772","volume":"11","author":"LC Junqueira","year":"1979","unstructured":"Junqueira LC, Bignolas G, Brentani RR. Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. Histochem J. 1979;11:447.","journal-title":"Histochem J"},{"key":"364_CR22","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1002\/hep.24315","volume":"53","author":"JA Thomas","year":"2011","unstructured":"Thomas JA, Pope C, Wojtacha D, Robson AJ, Gordon-Walker TT, Hartland S, Ramachandran P, Van Deemter M, Hume DA, Iredale JP, Forbes SJ. Macrophage therapy for murine liver fibrosis recruits host effector cells improving fibrosis, regeneration, and function. Hepatology. 2011;53:2003.","journal-title":"Hepatology"},{"key":"364_CR23","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1002\/eji.200324270","volume":"33","author":"N Rodig","year":"2003","unstructured":"Rodig N, Ryan T, Allen JA, Pang H, Grabie N, Chernova T, Greenfield EA, Liang SC, Sharpe AH, Lichtman AH, Freeman GJ. Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur J Immunol. 2003;33:3117.","journal-title":"Eur J Immunol"},{"key":"364_CR24","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","volume":"26","author":"RJ Johnston","year":"2014","unstructured":"Johnston RJ, Comps-Agrar L, Hackney J, Yu X, Huseni M, Yang Y, Park S, Javinal V, Chiu H, Irving B, Eaton DL, Grogan JL. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell. 2014;26:923.","journal-title":"Cancer Cell"},{"key":"364_CR25","doi-asserted-by":"publisher","first-page":"eadg0338","DOI":"10.1126\/scitranslmed.adg0338","volume":"16","author":"T Tadokoro","year":"2024","unstructured":"Tadokoro T, Murata S, Kato M, Ueno Y, Tsuchida T, Okumura A, Kuse Y, Konno T, Uchida Y, Yamakawa Y, Zushi M, Yajima M, Kobayashi T, Hasegawa S, Kawakatsu-Hatada Y, Hayashi Y, Osakabe S, Maeda T, Kimura K, Mori A, Tanaka M, Kamishibahara Y, Matsuo M, Nie YZ, Okamoto S, Oba T, Tanimizu N, Taniguchi H. Human iPSC-liver organoid transplantation reduces fibrosis through immunomodulation. Sci Transl Med. 2024;16:eadg0338.","journal-title":"Sci Transl Med."},{"key":"364_CR26","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/sctm.18-0105","volume":"8","author":"Y Watanabe","year":"2019","unstructured":"Watanabe Y, Tsuchiya A, Seino S, Kawata Y, Kojima Y, Ikarashi S, Starkey Lewis PJ, Lu WY, Kikuta J, Kawai H, Yamagiwa S, Forbes SJ, Ishii M, Terai S. Mesenchymal stem cells and induced bone marrow-derived macrophages synergistically improve liver fibrosis in mice. Stem Cells Transl Med. 2019;8:271.","journal-title":"Stem Cells Transl Med"},{"key":"364_CR27","doi-asserted-by":"publisher","first-page":"867940","DOI":"10.3389\/fendo.2022.867940","volume":"13","author":"JK Carter","year":"2022","unstructured":"Carter JK, Friedman SL. Hepatic stellate cell-immune interactions in NASH. Front Endocrinol (Lausanne). 2022;13:867940.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"364_CR28","doi-asserted-by":"publisher","first-page":"730176","DOI":"10.3389\/fcell.2021.730176","volume":"9","author":"Z Tan","year":"2021","unstructured":"Tan Z, Sun H, Xue T, Gan C, Liu H, Xie Y, Yao Y, Ye T. Liver fibrosis: therapeutic targets and advances in drug therapy. Front Cell Dev Biol. 2021;9:730176.","journal-title":"Front Cell Dev Biol"},{"key":"364_CR29","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.1182\/blood-2010-02-271981","volume":"116","author":"S Huber","year":"2010","unstructured":"Huber S, Hoffmann R, Muskens F, Voehringer D. Alternatively activated macrophages inhibit T-cell proliferation by Stat6-dependent expression of PD-L2. Blood. 2010;116:3311.","journal-title":"Blood"},{"key":"364_CR30","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41420-023-01347-8","volume":"9","author":"KJ Wu","year":"2023","unstructured":"Wu KJ, Qian QF, Zhou JR, Sun DL, Duan YF, Zhu X, Sartorius K, Lu YJ. Regulatory T cells (Tregs) in liver fibrosis. Cell Death Discov. 2023;9:53.","journal-title":"Cell Death Discov"}],"container-title":["Inflammation and Regeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41232-025-00364-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41232-025-00364-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41232-025-00364-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T07:46:06Z","timestamp":1737704766000},"score":1,"resource":{"primary":{"URL":"https:\/\/inflammregen.biomedcentral.com\/articles\/10.1186\/s41232-025-00364-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["364"],"URL":"https:\/\/doi.org\/10.1186\/s41232-025-00364-7","relation":{},"ISSN":["1880-8190"],"issn-type":[{"value":"1880-8190","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"assertion":[{"value":"26 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The experiments were approved by the Institutional Review Board at Hokkaido University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"M.M. and R.S. are employees of MEDINET Co., Ltd. K.S. received a research fund from MEDINET Co., Ltd. Rest of the authors declare that they have no competing financial interests. K.S. is the Deputy Editor-in-Chief of this journal.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}